What was the impact of the HCSC transaction on Cigna's financial results?

The divestiture of Medicare Advantage and related businesses to HCSC, completed on March 19, 2025, significantly impacted the Cigna Healthcare segment's revenue, which decreased by 18% in the quarter and 4% year-to-date. The transaction resulted in $4.2 billion in cash proceeds received at closing and contributed to a decrease in total medical customers by 5%. The gain on sale of businesses for the six months ended June 30, 2025, was impacted by this transaction.

How did Cigna's Pharmacy segment perform?

The Evernorth Health Services segment, which includes Pharmacy Benefit Services, performed strongly. Pharmacy revenues increased by 17% year-over-year for the six months ended June 30, 2025, reaching $102.28 billion. This growth was primarily driven by higher utilization of prescription drugs due to customer growth and an increase in claims composition. Pre-tax adjusted income from operations for this segment also grew by 5%.

What is the outlook for Cigna's investment portfolio?

Cigna's investment portfolio, primarily consisting of debt securities, saw a decrease in carrying value to $8.4 billion as of June 30, 2025. While the portfolio remains in a net unrealized depreciation position due to rising interest rates, 87% of debt securities are investment grade. The company anticipates continued volatility in private equity and real estate fund performance but does not expect losses to materially impact its financial condition or liquidity due to diversification and credit quality.

How is Cigna managing its capital and liquidity?

Cigna maintains robust liquidity through its subsidiary and parent company operations, including significant cash reserves and a $6.5 billion revolving credit facility. The company repurchased $2.6 billion of its common stock in the first six months of 2025 and declared a quarterly dividend of $1.51 per share. The debt-to-capitalization ratio stood at 43.3% as of June 30, 2025, indicating a well-managed capital structure.

CI 10-Q Quarterly Report Q2 FY2025 — Revenue, Net Income, EPS

Summary

The Cigna Group reported solid financial results for the six months ended June 30, 2025, demonstrating resilience and strategic execution. Total revenues increased by 13% year-over-year, reaching $132.68 billion, primarily driven by a significant 17% surge in Pharmacy revenues, fueled by customer growth in Evernorth Health Services. This strong top-line performance, coupled with disciplined cost management, resulted in a substantial 125% increase in Shareholders' Net Income to $2.86 billion, largely benefiting from the absence of a significant prior-year equity impairment. The company also successfully completed the divestiture of its Medicare Advantage and related businesses to HCSC, strengthening its strategic focus and financial position. Operationally, the company continues to execute its growth strategies across its Evernorth Health Services segment, which saw a 16% increase in adjusted revenues. While the Cigna Healthcare segment experienced an 18% decrease in adjusted revenues for the quarter due to the HCSC transaction, the underlying U.S. Healthcare businesses showed premium growth. The company maintained a strong liquidity position with significant undrawn committed capacity and a robust cash flow from operations, enabling continued capital deployment through dividends and share repurchases. Management remains confident in the company's ability to navigate market dynamics and deliver long-term shareholder value.

Financial Highlights

47 data points

Beta

Revenue

$67.18B

0.2% Gross Margin

Net Income

$1.53B

0.0% Net Margin

EPS (Diluted)

$5.71

Total Assets

$151.65B

Cash & Equivalents

$4.33B

Free Cash Flow

-$1.89B

Financial Statements

Beta

Revenue	$67.18B
Cost of Revenue	$53.27B
Gross Profit	$13.91B
SG&A Expenses	$3.43B
Operating Income	$2.31B
Interest Expense	$338.00M
Net Income	$1.53B
EPS (Basic)	$5.76
EPS (Diluted)	$5.71
Shares Outstanding (Diluted)	268.15M

Key Highlights

1Total Revenues increased by 13% to $132.68 billion for the six months ended June 30, 2025, compared to the prior year period.
2Shareholders' Net Income surged by 125% to $2.86 billion for the six months ended June 30, 2025, primarily due to the absence of a prior-year impairment charge.
3Pharmacy revenues saw a significant increase of 17% year-over-year, driven by customer growth and higher utilization in the Evernorth Health Services segment.
4Completed the divestiture of Medicare Advantage and related businesses to HCSC on March 19, 2025, receiving $4.2 billion in cash proceeds.
5Adjusted Income from Operations remained stable year-over-year at $3.77 billion for the six months ended June 30, 2025, reflecting strong operational performance.
6The company maintained a strong liquidity position with $6.5 billion in undrawn committed capacity under its revolving credit agreement as of June 30, 2025.
7Share repurchases totaled $2.6 billion for the six months ended June 30, 2025, demonstrating a commitment to returning capital to shareholders.

Cigna Group Quarterly Report for Q2 Ended Jun 30, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions